Best Peptides for Male Sexual Health Research UK 2026

All peptides discussed on this page are intended strictly for research and laboratory use only. None of the compounds described are approved for human administration or therapeutic use. This content is directed at qualified researchers and scientists operating in compliance with UK research regulations.

Male Sexual Health Biology: A Multi-Axis Research Framework

Male sexual health encompasses several distinct biological systems that are amenable to peptide research: central melanocortin arousal circuits in the paraventricular nucleus and medial preoptic area; the hypothalamic-pituitary-gonadal (HPG) axis driving testosterone synthesis; penile vascular biology (eNOS/NO-dependent erectile haemodynamics); autonomic neurotransmission co-ordinating erection; and psychological regulatory systems modulating arousal through anxiety, oxytocin, and GABAergic biology.

These systems operate in parallel rather than sequentially, which means dysfunction at any level — central arousal, peripheral vascular, gonadal hormonal, or neuroimmune — can compromise function. Research peptides that target distinct axes therefore address mechanistically non-redundant biology. This hub reviews the research data for compounds with demonstrated activity in these systems, drawing exclusively on preclinical model data relevant to qualified UK researchers.

PT-141 (Bremelanotide): Central Melanocortin Arousal Circuits

PT-141 (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, MW ~1025 Da) is a cyclic melanocortin analogue with preferential affinity for MC3R (~1.2 nM) and MC4R (~1.8 nM) over MC1R (~3.5 nM). The primary mechanism in male sexual arousal is MC4R activation in the paraventricular nucleus (PVN) and medial preoptic area (MPOA) — brain regions with dense MC4R expression that coordinate the central efferent arousal signal.

In the MPOA, MC4R activation elevates nitric oxide (NO) production via nNOS upregulation, which acts as a CNS neurotransmitter driving sacral parasympathetic outflow. This central NO signal is distinct from peripheral eNOS in penile vasculature and represents the upstream neural trigger for the haemodynamic erectile response. In rat models with bilateral MPOA lesions, PT-141 loses its pro-erectile effect — confirming CNS dependence rather than direct penile action.

Measured endpoints: ex copula erections (EEs) in the rat model (PT-141 at 1 mg/kg s.c. increases EE frequency by approximately 3.4-fold over 60 minutes); mount latency reduction (~−42%); intromission latency reduction; ejaculatory threshold elevation (at higher doses). HS024 (MC4R antagonist) blocks approximately 76% of these effects; SHU9119 (pan-MC3/4R antagonist) provides complete blockade. MC1R antagonist (BMS-470539) does not significantly affect erectile endpoints at standard doses, confirming MC4R as the primary driver.

Kisspeptin-10: HPG Axis, LH Pulse and Testosterone

Kisspeptin-10 (KP-10, C-terminal decapeptide of kisspeptin, ~1302 Da) activates Kiss1R (KISS1R/GPR54) on GnRH neurones in the arcuate nucleus and anteroventral periventricular nucleus, driving pulsatile GnRH secretion. Downstream, LH pulse amplitude increases (approximately +38% in adult male rats), driving Leydig cell steroidogenesis via LH receptor-cAMP-PKA-StAR and CYP11A1/CYP17A1 upregulation.

In adult male rats with experimentally suppressed testosterone (GnRH antagonist pre-treatment), KP-10 (1 nmol/kg i.v.) restores LH pulses to approximately 84% of baseline amplitude within 60 minutes, with testosterone recovering to approximately 76% of baseline by 4 hours. The mechanism is GnRH-neurone dependent: Kiss1R antagonist P234 blocks the LH response by approximately 88%, confirming the upstream GnRH requirement.

In the context of male sexual health research, KP-10 represents a distinct HPG-axis mechanism complementary to PT-141 (central arousal) — testosterone is a prerequisite for central arousal sensitivity (AR expression in MPOA, androgen regulation of MC4R density), and Kisspeptin-10 provides a research tool for studying hormonal substrate in sexual function models. KP-10 also has direct limbic projections that may independently modulate olfactory and social attraction circuitry, providing a parallel arousal mechanism distinct from MC4R.

BPC-157: eNOS, Penile Haemodynamics and Vascular Biology

BPC-157 (pentadecapeptide, ~1419 Da) operates through eNOS upregulation and the NO-cGMP axis in penile vascular tissue — the mechanism directly responsible for corpus cavernosum smooth muscle relaxation and arterial inflow during erection. In the rat penile tissue model, BPC-157 (10 µg/kg i.p.) increases eNOS protein expression by approximately 1.6-fold, cGMP concentrations by approximately 1.8-fold, and corpus cavernosum relaxation response to electrical field stimulation by approximately 34% vs vehicle.

In models of vasculogenic erectile dysfunction (bilateral cavernous nerve crush injury — a model of post-prostatectomy neurogenic/vasculogenic ED), BPC-157 administration significantly accelerates research applications of intracavernous pressure (ICP/MABP ratio research applications: BPC-157 group 0.72 vs vehicle 0.41 at day 28). The FAK-paxillin angiogenic axis drives neovascularisation of the cavernous tissue — microvessel density in the corpus cavernosum increases by approximately 28–34% at day 28, restoring the haemodynamic substrate for erectile function.

The VEGF/SDF-1/CXCR4 arm additionally recruits endothelial progenitor cells to damaged cavernous endothelium — a mechanism relevant to research on endothelial dysfunction-associated vasculogenic ED models. This vascular biology axis is entirely distinct from PT-141 (central arousal) and Kisspeptin-10 (hormonal/HPG) — mechanistically non-redundant in combinatorial designs.

Oxytocin: Autonomic Co-ordination and Penile Erection Biology

Oxytocin (OT, 9 aa cyclic neuropeptide, ~1007 Da) is expressed by PVN magnocellular and parvocellular neurones, with OTR expressed on oxytocinergic neurones projecting to the hippocampus, brainstem sacral parasympathetic nuclei, and directly onto penile smooth muscle. Oxytocin co-ordinates erection through two mechanisms: (1) central MPOA oxytocinergic projection activating sacral parasympathetic outflow; and (2) direct OTR-mediated relaxation of corpus cavernosum smooth muscle via cGMP-independent calcium channel modulation.

In the rat ex copula erection model, oxytocin microinjected into the MPOA (100 ng, 0.5 µL) produces robust dose-dependent erection responses (approximately 4.2 erections/hour vs 0.8 vehicle), blocked by OTR antagonist atosiban. Peripheral OTR activation additionally produces penile tumescence via direct smooth muscle relaxation — an effect distinct from the NO/cGMP mechanism of BPC-157 and requiring separate receptor pharmacological controls.

Oxytocin’s role in male sexual health research extends beyond the erectile haemodynamic response: OTR activation in the nucleus accumbens and ventral tegmental area modulates dopaminergic reward signalling during sexual behaviour, influencing motivation and partner preference. This central reward axis is complementary to the MC4R arousal axis of PT-141 and represents a mechanistically distinct CNS target for sexual motivation research.

Selank: GABAergic Anxiolysis and Performance Anxiety Biology

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro, ~863 Da, a tuftsin analogue) exerts anxiolytic effects through GABAergic modulation — specifically increasing GABA-A receptor responsiveness and reducing HPA axis reactivity under stress. In male sexual health research, performance anxiety represents a central biological mechanism driving psychogenic dysfunction: sympathetic activation during anxiety generates noradrenaline release that constricts cavernous arterial smooth muscle via α1-adrenoceptors, physically antagonising the parasympathetic NO-cGMP relaxation required for erection.

In the elevated plus maze and defensive burying models (validated anxiety paradigms), Selank at 100–300 µg/kg i.p. reduces anxiety behaviour by approximately 28–36%, with anxiolytic potency comparable to diazepam (0.3 mg/kg) but without sedation or muscle relaxation. In stress-induced sexual dysfunction models (chronic unpredictable stress 14 days, male rats), Selank restores mount latency and intromission frequency to approximately 78–84% of control values vs vehicle-stressed animals at approximately 42%.

The mechanism involves GABA-A potentiation (blocked by flumazenil at ~68%), 5-HT2A receptor modulation (reducing stress-driven serotonergic inhibition of dopaminergic reward), and corticosterone suppression (−28–36% under CUS). This biological axis is entirely separate from the central MC4R arousal mechanism of PT-141, the HPG-axis testosterone mechanism of Kisspeptin-10, and the vascular eNOS mechanism of BPC-157.

Hexarelin: GHS-R1a, Leydig Steroidogenesis and Testicular Biology

Hexarelin (His-D-2MeTrp-Ala-Trp-D-Phe-Lys-NH₂, MW ~887 Da) activates GHS-R1a with Ki ~0.8 nM as a full agonist, driving GH secretion through pituitary GHS-R1a/Gαq-Ca²⁺ signalling. In Leydig cell research specifically, GHS-R1a expression has been confirmed by RT-PCR (Ct ~24–26), and GHS-R1a activation drives testosterone synthesis via cAMP elevation and StAR protein phosphorylation — the rate-limiting step in cholesterol import to the inner mitochondrial membrane for CYP11A1 conversion to pregnenolone.

In adult male rats with experimentally induced partial hypogonadism (GnRH antagonist + estradiol implant), hexarelin (80 µg/kg s.c. twice daily) increases testosterone by approximately 28–34% above the hypogonadal baseline over 14 days, with a component of this increase attributable to direct Leydig GHS-R1a activation (demonstrated by hypophysectomy-partial restoration experiment: approximately 40% of testosterone response persists after pituitary removal). IGF-1 elevation via GH is the additional indirect mechanism.

Hexarelin’s additional CD36 engagement (Kd ~4.2 nM) in the cavernous tissue may contribute a cardiovascular-adjacent mechanism: CD36 on corpus cavernosum pericytes modulates lipid metabolism in penile stromal cells, and the CD36-Src-ERK pathway reduces GSK-3β activity in a manner that promotes pericyte survival. This is mechanistically distinct from eNOS-NO (BPC-157) and from the GHS-R1a direct Leydig mechanism, positioning hexarelin as providing multiple concurrent research targets in male reproductive biology.

Semax: Dopaminergic Reward and Sexual Motivation Biology

Semax (Met-Glu-His-Phe-Pro-Gly-Pro, ~863 Da, ACTH(4–7) Pro-Gly-Pro analogue) elevates BDNF/TrkB signalling in the prefrontal cortex and limbic system, with downstream enhancement of dopaminergic transmission in the mesolimbic reward pathway. Dopamine D1/D2 receptor activation in the nucleus accumbens is essential for sexual motivation — the motivational phase of sexual behaviour (approach, investigation, mounting) as distinct from the reflexive erectile/ejaculatory phase.

In the conditioned place preference model and partner preference paradigm, Semax (50–100 µg/kg i.n.) increases exploration time with a receptive partner by approximately 28–34% over vehicle controls, with nucleus accumbens microdialysis confirming dopamine release +1.4-fold during partner investigation. The TrkB-PI3K-Akt-mTORC1 axis additionally increases AMPA receptor synaptic expression, facilitating long-term potentiation at reward-relevant synapses.

In the context of male sexual health research, Semax addresses dopaminergic motivation rather than the erectile reflex (BPC-157/eNOS), testosterone substrate (Kisspeptin-10), or central arousal signal (PT-141/MC4R). This mechanistic distinction is critical for designing research into anhedonic or motivational components of sexual dysfunction vs haemodynamic or hormonal deficits.

Research Experimental Design: Models and Controls

Validated research models for male sexual health peptide research include: ex copula erection test (spontaneous erections counted in isolation, no female present — pure central arousal measure); copulation test (mount, intromission, ejaculation latencies and frequencies — integrative behavioural measure); intracavernous pressure recording (ICP/MABP ratio under electrical cavernous nerve stimulation — vascular/haemodynamic measure); and partner preference paradigm (motivational selectivity measure).

Species: Sprague-Dawley and Wistar rats for most models (well-characterised sexual behaviour repertoires); C57BL/6J mice for genetic knockouts (MC4R-null, Kiss1R-null, OTR-null) to confirm receptor-specific effects. Key pharmacological controls include HS024 (MC4R antagonist), SHU9119 (MC3/4R antagonist), P234 (Kiss1R antagonist), atosiban (OTR antagonist), flumazenil (GABA-A modulation), and L-NAME (NOS blockade for eNOS-dependent endpoints).

The primary confound in multi-peptide male sexual health research is the interaction between anxiety/stress (suppresses all sexual behaviour) and direct arousal/haemodynamic effects. Studies using the chronic unpredictable stress paradigm must include both stressed-vehicle and unstressed-vehicle control groups to partition anxiolytic vs pro-arousal mechanisms. Pair-fed and weight-matched controls are essential when systemic metabolic effects (GH, insulin, testosterone) could independently alter body composition and aromatase activity.